Medindia

X

Bronchodilators Appear Associated With Increased Risk of Cardiovascular Events: Study

by Rukmani Krishna on  May 22, 2013 at 11:55 PM Research News   - G J E 4
A study of older patients with chronic obstructive pulmonary disease (COPD) suggests that new use of the long-acting bronchodilators β-agonists and anticholinergics was associated with similar increased risks of cardiovascular events. The study was published Online First by JAMA Internal Medicine, a JAMA Network publication.
 Bronchodilators Appear Associated With Increased Risk of Cardiovascular Events: Study
Bronchodilators Appear Associated With Increased Risk of Cardiovascular Events: Study
Advertisement

COPD affects more than 1 in 4 Americans older than 35 years of age and is the third leading cause of death in the United States. Medications are a mainstay of management of the disease. While there is little controversy about the effectiveness of long-acting β-agonists (LABAs) and long-acting anticholinergics (LAAs), their cardiovascular safety remains a matter of debate, according to the study background.

Advertisement
Andrea Gershon, M.D., M.S., of the Institute for Clinical Evaluative Sciences, Ontario, Canada, and colleagues conducted a nested case control analysis of a retrospective cohort study and compared the risk of cardiovascular events between patients newly prescribed the inhaled long-acting medications.

The study used health care databases from Ontario and included all individuals 66 years or older with a diagnosis of COPD who were treated from September 2003 through March 2009.

Of 191,005 eligible patients, 53,532 (28 percent) had a hospitalization or an emergency department visit for a cardiovascular event. According to the results, newly prescribed long-acting inhaled bronchodilators β-agonists and anticholinergics were associated with higher risk of a cardiovascular event compared with nonuse of those medications (respective adjusted odds ratios, 1.31 and 1.14). The results also indicate there was no significant difference in events between the two medications.

"Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events. Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class," the study concludes.

Source: Newswise
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All